Platelet-Rich Plasma (PRP) Treatment

PreclinicalBiologic

Platelet-Rich Plasma (PRP) Treatment is one of 2 biologic programs targeting Vulvar Lichen Sclerosus. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Vulvar Lichen SclerosusNot yet recruiting

Vulvar Lichen SclerosusPreclinical

Not yet recruiting

Competition

Competitive Landscape

2 competitors in Vulvar Lichen Sclerosus

#DrugCompanyPhaseTrials

Trexall

Jazz Pharmaceuticals

Phase 2

1 2

Platelet-Rich Plasma (PRP) Treatment

MMilosz Pietrus

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

N/ANot yet recruiting

Vulvar Lichen Sclerosus

NCT07240389

Clinical

Trials by Indication[1]

Vulvar Lichen Sclerosus1 trial

Treatment of Vulvar Lichen Sclerosus With Corticosteroid Ointment, Calcineurin Inhibitor Ointment, and Platelet-Rich Plasma (PRP) Therapy.

Not yet recruiting·MMilosz Pietrus·N/A·NCT07240389·45 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Platelet-Rich Plasma (PRP) Treatment. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Platelet-Rich Plasma (PRP) Treatment compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Platelet-Rich Plasma (PRP) Treatment. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Milosz Pietrus company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: MMilosz Pietrus

Platelet-Rich Plasma (PRP) Treatment

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Vulvar Lichen Sclerosus1 trial

References

Drug Info

Quick Facts

Related News